Amgen Inc has selected two preclinical European biotech companies for deals in oncology with the expectation that they will help the company deliver new treatments for acute myeloid leukaemia and small cell lung and colorectal cancers. Total outlays for the two deals could be as much as $1.46 billion. The largest transaction involves the acquisition of Dark Blue Therapeutics Ltd of the UK for up to $840 million. The smaller deal is a collaboration with Germany-based DISCO Pharmaceuticals GmbH which is potentially valued at $618 million plus royalties.
